We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Maryland-based Novavax has teamed up with Takeda Pharmaceutical Co. to commercialize Novavax’s COVID-19 vaccine candidate NVX-CoV2373 in Japan. Read More
Gilead Sciences said it should be able to meet international demand for remdesivir in October, thanks to improvements in its own processes and an expanded manufacturing network. Read More
Novavax signed a licensing agreement with the Serum Institute of India yesterday to commercialize the drugmaker’s COVID-19 vaccine candidate in low- and middle-income countries, as well as in India. Read More
AstraZeneca (AZ) has reached an agreement with China’s Kangtai Biologics to help develop and manufacture its promising coronavirus candidate AZD1222, the first deal the British drugmaker has forged for its experimental vaccine in China. Read More
Moderna is offering its COVID-19 vaccine candidate at $32 to $37 per dose for smaller-scale supply agreements, the company’s CEO Stéphane Bancel said Wednesday. Read More
Johnson & Johnson (J&J) has secured a $1 billion contract from the U.S. government to manufacture 100 million doses of its COVID-19 vaccine candidate Ad26.COV2.S. Read More
Pfizer and BioNTech have signed an agreement with Japan’s Ministry of Health to supply the country with 120 million doses of their COVID-19 vaccine. Read More